Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults

ORCID
0000-0001-7818-9841
Affiliation
Danish Headache Center, Department of Neurology, Rigshospitalet – Glostrup, Denmark
Deen, Marie;
ORCID
0000-0001-6355-7947
Affiliation
Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy
Martinelli, Daniele;
Affiliation
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands
Pijpers, Judith;
GND
11811901X
ORCID
0000-0002-6556-8612
LSF
13450
Affiliation
Medical Faculty of the University Duisburg-Essen, Essen Germany
Diener, Hans-Christoph;
GND
107239877X
ORCID
0000-0001-9467-5567
Affiliation
Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Silberstein, Stephen;
Affiliation
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands
Ferrari, Michel D.;
ORCID
0000-0003-0951-5804
Affiliation
Danish Headache Center, Department of Neurology, Rigshospitalet – Glostrup, Denmark
Ashina, Messoud;
ORCID
0000-0003-1513-2113
Affiliation
Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy
Tassorelli, Cristina;
GND
1221688715
ORCID
0000-0002-4536-9974
Affiliation
Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Yuan, Hsiangkuo

Introduction: Since the definition of chronic migraine as a new disease entity in 2004, numerous clinical trials have examined the efficacy of preventive treatments in chronic migraine. Our aim was to assess the adherence of these trials to the Guidelines of the International Headache Society published in 2008.

Methods: We searched PubMed for controlled clinical trials investigating preventive treatment for chronic migraine in adults designed after the release of the Guidelines and published until December 2017. Trial quality was evaluated with a 13-item scoring system enlisting essential recommendations adapted from the Guidelines.

Results: Out of 3352 retrieved records, we included 16 papers in the analysis dealing with pharmacological treatment of chronic migraine. The median score was 6.5 (range 2–13). All trials were randomized, the large majority (81.25%) were placebo-controlled and double-blinded (87.5%). Adherence was lowest on i) a priori definition of outcomes (31.25%), ii) primary endpoint definition (37.5%%) and iii) trial registration (37.5%).

Discussion: Most clinical trials adhered to the recommendations of the IHS, whereas adherence to migraine-specific recommendations was lower. Greater awareness and adherence to the guidelines are essential to improve the quality of clinical trials, validity of publications and the generalizability of the results.

Cite

Citation style:
Could not load citation form.

Rights

License Holder:

© International Headache Society 2019

Use and reproduction:
All rights reserved

Export